Papers: 10.1016/j.eclinm.2020.100693
https://doi.org/10.1016/j.eclinm.2020.100693
Consequences to patients, clinicians, and manufacturers when very serious adverse drug reactions are identified (1997–2019): A qualitative analysis from the Southern Network on Adverse Reactions (SONAR)
Cited by: 2
Author(s): Charles L. Bennett, Shamia Hoque, Nancy F. Olivieri, Matthew A. Taylor, David M. Aboulafia, Courtney Lubaczewski, Ashley Bennett, Jay Vemula, Benjamin Schooley, Bartlett J. Witherspoon, Ashley Caitlin Godwin, Paul S. Ray, Paul R. Yarnold, Henry C. Ausdenmoore, Marc L. Fishman, Georgne Herring, Anne Ventrone, Juan Aldaco, William J. M. Hrushesky, John Restaino, Henrik S. Thomsen, Robert E. Marx, Cesar A. Migliorati, Salvatore L. Ruggiero, Chadi Nabhan, Kenneth R. Carson, June M. McKoy, Y. Tony Yang, Martin W. Schoen, Kevin Knopf, Linda W. Martin, Oliver Sartor, Steven T. Rosen, William K. Smith
Published: almost 6 years ago